Calreticulin Recombinant Rabbit Monoclonal Antibody [SU37-03]
Usd: 205 Special Discount
Specification
Safety datasheet
Overview
Product Name
Calreticulin Recombinant Rabbit Monoclonal Antibody [SU37-03]
Antibody Type
Recombinant Rabbit monoclonal Antibody
Immunogen
Synthetic peptide within Human Calreticulin aa 40-89 / 417.
Species Reactivity
Human, Mouse, Rat
Validated Applications
WB, IHC-P, IF-Cell, FC, IP
Molecular Weight
Predicted band size: 48 kDa
Positive Control
HepG2 cell lysate, HeLa cell lysate, HL-60 cell lysate, C2C12 cell lysate, C6 cell lysate, Mouse liver tissue lysate, Rat liver tissue lysate, human liver tissue, human liver carcinoma tissue, HeLa.
Conjugation
unconjugated
Clone Number
SU37-03
RRID
Reactivity Data
Tested Verified (internally validated)
Published Reported in literature (not internally validated)
Predicted Predicted reactive (based on sequence homology)
Not recommended Not recommended (failed internal validation)
| WB | IHC-P | IF-Cell | FC | IP | |
|---|---|---|---|---|---|
| Human |
|
|
|
|
|
| Mouse |
|
|
|
|
|
| Rat |
|
|
|
Product Features
Form
Liquid
Concentration
Storage Instructions
Shipped at 4℃. Store at +4℃ short term (1-2 weeks). Store at -20℃ long term.
Storage Buffer
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Isotype
IgG
Purification Method
Protein A affinity purified.
Application Dilution
-
WB
-
1:50,000
-
IHC-P
-
1:5,000
-
IF-Cell
-
1:5,000
-
FC
-
1:2,000
-
IP
-
1-2μg/sample
Target
Function
Calnexin and calregulin (also called calreticulin) are calcium-binding proteins that are localized to the endoplasmic reticulum, Calnexin to the membrane and calregulin to the lumen. Calnexin is a type I membrane protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may play a role in assisting with protein assembly and in retaining unassembled protein subunits in the endoplasmic reticulum. Calregulin has both low- and high-affinity calcium-binding sites. Neither Calnexin nor calregulin contains the calcium-binding "E-F hand" motif found in calmodulins. Calnexin and calregulin are important for the maturation of glycoproteins in the endoplasmic reticulum and appear to bind many of the same proteins.
Background References
1. Kojima Y et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest 124:1083-97 (2014).
2. Angelova AL et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol 88:5263-76 (2014).
Sequence Similarity
Belongs to the calreticulin family.
Subcellular Location
Endoplasmic reticulum lumen, Cytoplasm, Secreted, Cell surface, Sarcoplasmic reticulum lumen, nucleus.
Synonyms
Autoantigen RO antibody
CALR antibody
CALR protein antibody
CALR_HUMAN antibody
Calregulin antibody
Calreticulin antibody
cC1qR antibody
CRP55 antibody
CRT antibody
CRTC antibody
ExpandAutoantigen RO antibody
CALR antibody
CALR protein antibody
CALR_HUMAN antibody
Calregulin antibody
Calreticulin antibody
cC1qR antibody
CRP55 antibody
CRT antibody
CRTC antibody
Endoplasmic reticulum resident protein 60 antibody
Epididymis secretory sperm binding protein Li 99n antibody
ERp60 antibody
FLJ26680 antibody
grp60 antibody
HACBP antibody
HEL S 99n antibody
RO antibody
Sicca syndrome antigen A (autoantigen Ro
calreticulin) antibody
Sicca syndrome antigen A antibody
SSA antibody
CollapseImages
-
Application: Immunocytochemistry (IF-cell)
Species: Human
Sample: HeLa (Human cervix adenocarcinoma epithelial cell)
Fixation: Ice cold 100% methanol, 5 minutes at room temperature.
Permeabilization: /
Blocking: 1% BSA + 10% normal goat serum, 1 hour at room temperature.
Antibody dilution buffer: 1% BSA in PBST.
Primary antibody: ET1608-60, 1/5,000, overnight at 4℃.
Secondary antibody: Goat Anti-Rabbit IgG (iFluor™ 488, HA1121), 45 minutes at room temperature.
Counterstain: Beta tubulin (HA601187, Red), 1/100, overnight at 4℃. The Nuclear counterstain was DAPI (Blue). -
Western blot analysis of Calreticulin on different lysates with Rabbit anti-Calreticulin antibody (ET1608-60) at 1/50,000 dilution and competitor's antibody at 1/5,000 dilution.
Lane 1: HepG2 cell lysate
Lane 2: HeLa cell lysate
Lane 3: HL-60 cell lysate
Lane 4: C2C12 cell lysate
Lane 5: C6 cell lysate
Lane 6: Mouse liver tissue lysate
Lane 7: Rat liver tissue lysate
Lysates/proteins at 10 µg/Lane.
Predicted band size: 48 kDa
Observed band size: 55 kDa
Exposure time: 1 minute 2 seconds; ECL: K1801;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (ET1608-60) at 1/50,000 dilution and competitor's antibody at 1/5,000 dilution were used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature. -
☑ Knockdown (KD)
Western blot analysis of Calreticulin on different lysates with Rabbit anti-Calreticulin antibody (ET1608-60) at 1/50,000 dilution.
Lane 1: HAP1-parental cell lysate (10 µg/Lane)
Lane 2: HAP1-Calreticulin KD cell lysate (10 µg/Lane)
Predicted band size: 48 kDa
Observed band size: 55 kDa
Exposure time: 30 seconds; ECL: K1801;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (ET1608-60) at 1/50,000 dilution was used in K1803 at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature. -
☑ Knockdown (KD)
Western blot analysis of Calreticulin on different lysates with Rabbit anti-Calreticulin antibody (ET1608-60) at 1/50,000 dilution.
Lane 1: HeLa-si NT cell lysate (10 µg/Lane)
Lane 2: HeLa-si Calreticulin cell lysate (10 µg/Lane)
Predicted band size: 48 kDa
Observed band size: 55 kDa
Exposure time: 13 seconds; ECL: K1801;
4-20% SDS-PAGE gel.
Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (ET1608-60) at 1/50,000 dilution was used in 5% NFDM/TBST at 4℃ overnight. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1/50,000 dilution was used for 1 hour at room temperature. -
Immunohistochemical analysis of paraffin-embedded human liver tissue with Rabbit anti-Calreticulin antibody (ET1608-60) at 1/5,000 dilution.
The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (ET1608-60) at 1/5,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human liver carcinoma tissue with Rabbit anti-Calreticulin antibody (ET1608-60) at 1/5,000 dilution.
The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (ET1608-60) at 1/5,000 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Flow cytometric analysis of HeLa cells labeling Calreticulin.
Cells were fixed and permeabilized. Then stained with the primary antibody (ET1608-60, 1/2,000) (red) compared with Rabbit IgG Isotype Control (green). After incubation of the primary antibody at +4℃ for an hour, the cells were stained with a iFluor™ 488 conjugate-Goat anti-Rabbit IgG Secondary antibody (HA1121) at 1/1,000 dilution for 30 minutes at +4℃. Unlabelled sample was used as a control (cells without incubation with primary antibody; black). -
Calreticulin was immunoprecipitated in 0.2mg HeLa cell lysate with ET1608-60 at 2 µg/10 µl beads. Western blot was performed from the immunoprecipitate using ET1608-60 at 1/1,000 dilution. Anti-Rabbit IgG for IP Nano-secondary antibody (NBI01H) at 1/5,000 dilution was used for 1 hour at room temperature.
Lane 1: HeLa cell lysate (input)
Lane 2: Rabbit IgG instead of ET1608-60 in HeLa cell lysate
Lane 3: ET1608-60 IP in HeLa cell lysate
Blocking/Dilution buffer: 5% NFDM/TBST
Exposure time: 24 seconds
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Citation
-
Manganese-Activatable Nano-Hydroxyapatite Nanoparticles as Self-Adjuvanting STING Activators for Synergistic Melanoma Therapy
Journal: Journal Of Materials Chemistry B
DOI: 10.1039/D5TB02759D
IF: 5.7
Application: FC
Reactivity: Mouse
Publish date: 2026 Mar
-
A nanoplatform that induces dual-amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy
Journal: BMEMat
DOI: 10.1002/bmm2.70083
IF: 15.5
Application: WB,IF-cell
Reactivity: Mouse
Publish date: 2026 Mar
-
IMB5023: Dual suppression of microtubule assembly and STAT3 signaling overcomes chemoresistance and activates antitumor immunity
Journal: Biochemical Pharmacology
DOI: 10.1016/j.bcp.2026.117812
IF: 5.6
Application: FC
Reactivity: Human,Mouse
Publish date: 2026 Feb
-
FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy
Journal: Oncogene
DOI: 10.1038/s41388-025-03558-y
IF: 7.3
Application: IF-cell
Reactivity: Mouse
Publish date: 2025 Sept
-
Mito-Specific “Trojan Horse” Nanotherapy: Synergistic Antitumor Immunotherapy via Dual Modulation Mitochondrial Metabolism and Glycolysis
Journal: ACS Applied Nano Materials
DOI: 10.1021/acsnano.5c08486
IF: 16
Application: IF-cell
Reactivity: Mouse
Publish date: 2025 Oct
-
Penetrative Biomimetic Nanovehicle Boosts Immunotherapy in Triple-Negative Breast Cancer via SOS1 Blockade
Journal: Asian Journal of Pharmaceutical Sciences
DOI: 10.1016/j.ajps.2025.101064
IF: 10.7
Application: FC
Reactivity: Mouse
Publish date: 2025 May
-
Platform-based BST-2-targeted microbubbles enhance HIFU therapy and effectively inhibit prostate cancer residual growth
Journal: International Journal of Hyperthermia
DOI: 10.1080/02656736.2025.2511035
IF: 3
Application: IF-tissue
Reactivity: Mouse
Publish date: 2025 May
-
Modification of RNF183 via m6A Methylation Mediates Podocyte Dysfunction in Diabetic Nephropathy by Regulating PKM2 Ubiquitination and Degradation
Journal: Cells
DOI: 10.3390/cells14050365
IF: 5.1
Application: IF-cell
Reactivity: Human
Publish date: 2025 Mar
-
Spatiotemporal-Controlled Nanoagonists Triggered STING Activation for Cascade-Amplified Photothermal Metalloimmunotherapy
Journal: Biomacromolecules
DOI: 10.1021/acs.biomac.4c01774
IF: 5.4
Application: IF-cell
Reactivity: Mouse
Publish date: 2025 Jul
-
Synergizing Ferroptosis and Immunotherapy via a PROTAC/PDT/HPK1 Inhibitor-Loaded Nanoplatform for Enhanced Antitumor Efficacy
Journal: Advanced Functional Materials
DOI: 10.1002/adfm.202507906
IF: 19
Application: WB
Reactivity: Mouse
Publish date: 2025 Jul
-
Schisandra chinensis lignans exerts endocannabinoids-like antidepressive effect: The phagocytotic relationship of activated CB2R-mediated M2 microglia and “stressed-but-viable” neuron
Journal: Journal Of Ethnopharmacology
DOI:
IF: 4.8
Application: WB
Reactivity: Mouse,Rat
Publish date: 2025 Jan
-
Schisandra chinensis lignans exerts endocannabinoids-like antidepressive effect: The phagocytotic relationship of activated CB2R-mediated M2 microglia and “stressed-but-viable” neuron
Journal: JOURNAL OF ETHNOPHARMACOLOGY
DOI: 10.1016/j.jep.2025.119385
IF: 5.4
Application: IF-Cell,WB
Reactivity: Rat,Mouse
Publish date: 2025 Jan
-
Honokiol-Magnolol-Baicalin Possesses Synergistic Anticancer Potential and Enhances the Efficacy of Anti-PD-1 Immunotherapy in Colorectal Cancer by Triggering GSDME-Dependent Pyroptosis
Journal: Advanced Science
DOI: 10.1002/advs.202417022
IF: 14.3
Application: IF-tissue
Reactivity: Mouse
Publish date: 2025 Feb
-
A fusion of oncolytic viruses and bispecific T-cell engagers for triple negative breast cancer immunotherapy
Journal: Chemical Engineering Journal
DOI: 10.1016/j.cej.2025.160853
IF: 13.3
Application: IF-cell
Reactivity: Mouse
Publish date: 2025 Feb
-
An Immune Nanoenhancer Revitalizes Chemotherapeutics to Tailor Tumor-Derived dsDNA for Anticancer Immunoengineering
Journal: Advanced Materials
DOI: 10.1002/adma.202516524
IF: 26.8
Application: IF-cell
Reactivity: Mouse
Publish date: 2025 Dec
-
Disulfidptosis Nanoinducer Interrupts Tumor Metabolic Privilege to Boost Sustained Immunotherapy
Journal: ACS Applied Nano Materials
DOI: 10.1021/acsnano.5c08432
IF: 16
Application: IF-cell
Reactivity: Mouse
Publish date: 2025 Aug
-
Harnessing Membrane-Targeting Photosensitizers to Evoke Ferroptosis and Pyroptosis Dual-Modal Cell Death for Antitumor Therapy
Journal: Molecular Pharmaceutics
DOI: 10.1021/acs.molpharmaceut.5c01042
IF: 4.5
Application: IF-cell
Reactivity: Mouse
Publish date: 2025 Aug
-
GPX2 inhibition enhances antitumor efficacy of lenvatinib via promoting immunogenic cell death in hepatocellular carcinoma
Journal: Journal Of Translational Medicine
DOI: 10.1186/s12967-025-06468-5
IF: 6.1
Application: IF-cell
Reactivity: Human,Mouse
Publish date: 2025 Apr
-
Triggering Pyroptosis by Doxorubicin-Loaded Multifunctional Nanoparticles in Combination with Decitabine for Breast Cancer Chemoimmunotherapy
Journal: Biological And Medical Applications Of Materials And Interfaces
DOI:
IF: 8.3
Application: IF-cell
Reactivity: Human
Publish date: 2024 Oct
-
A biomimetic solution, albumin–doxorubicin molecular complex, targeting tumor and tumor-draining lymph nodes
Journal: Journal Of Materials Chemistry B
DOI:
IF: 6.1
Application: IHC-P
Reactivity: Mouse
Publish date: 2024 Nov
-
Cell surface patching via CXCR4-targeted nanothreads for cancer metastasis inhibition
Journal: Nature Communications
DOI:
IF: 16.6
Application: FC
Reactivity: Mouse
Publish date: 2024 Mar
-
A Self-Cascade Oxygen-Generating Nanomedicine for Multimodal Tumor Therapy
Journal: Small
DOI: 10.1002/smll.202403523
IF: 13
Application: IF-cell
Reactivity: Mouse
Publish date: 2024 Jul
-
Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors
Journal: Small
DOI: 10.1002/smll.202308265
IF: 13.3
Application: FC
Reactivity: Human,Mouse
Publish date: 2024 Jan
-
High Intensity Focused Ultrasound-Driven Nanomotor for Effective Ferroptosis-Immunotherapy of TNBC
Journal: Advanced Science
DOI: 10.1002/advs.202305546
IF: 14.3
Application: FC
Reactivity: Mouse
Publish date: 2024 Feb
-
A sodium alginate-based injectable hydrogel system for locoregional treatment of colorectal cancer by eliciting pyroptosis and apoptosis
Journal: International Journal Of Biological Macromolecules
DOI: 10.1016/j.ijbiomac.2024.139345
IF: 7.7
Application: WB
Reactivity: Mouse
Publish date: 2024 Dec
-
Metal-organic framework-based photodynamic combined immunotherapy against the distant development of triple-negative breast cancer
Journal: Biomaterials Research
DOI: 10.1186/s40824-023-00447-x
IF: 11.3
Application: WB
Reactivity: Mouse
Publish date: 2023 Nov
-
Systematic In-Depth Proteomic Analysis of Mitochondria-Associated Endoplasmic Reticulum Membranes in Mouse and Human Testes
Journal: Proteomics.
DOI:
IF: 3.984
Application: WB
Reactivity: Human,Mouse
Publish date: 2018 Jul